COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo

Grangemouth

Our Grangemouth, UK facility is USFDA, MHRA & PMDA Japan inspected, offering development, clinical & commercial scale manufacture of bio-conjugates including Antibody Drug Conjugates (ADCs) since 2004.  The site provides full process & analytical development services to support proof-of-concept & Toxicology studies with commercial manufacture of ADCs since 2012.  

Location Address:

Piramal Healthcare UK Ltd., Piramal Pharma Solutions, Earls Road, Grangemouth, Stirlingshire, Scotland, UK, FK3 8XG

Contact: +44 (0)1324 498300

Specialized Capabilities

  • Three dedicated GMP production suites for clinical and commercial manufacturing
  • Multi-product manufacturing facility characterized by specialized or single-use product-contact manufacturing components
  • ISO 7 processing area and ISO 5 filling area
  • Site quality management system to ICH Q7

Featured Services

  • GMP manufacturing of clinical and commercial supplies
  • Product commercialization and scale-up
  • Process development, optimization, and characterization
  • Preclinical and toxicology batch preparations
  • Analytical and bio-analytical method development and validation
  • Proof of concept studies
  • Stability studies and testing

Salient Features

  • World leader in ADC and bioconjugation process development, GMP manufacture, and scale-up
  • First CMO to offer contract development and manufacturing service in ADCs
  • Worked with >180 unique bioconjugate platforms including all significant ADC drug-linker payloads and numerous proprietary molecules
  • Over 450 lab-scale, toxicology and pre-clinical batches in development facility
  • Over 500 GMP batches including over 200 commercial lots
  • US FDA, UK MHRA, Japan PMDA, Brazil ANVISA, and Turkey Ministry of Health inspected for commercial manufacturing
Virtual Tour
Take a virtual tour of our Grangemouth Plant
Virtual Tour
Take a video tour of our Grangemouth Plant
Virtual Tour
Modern Slavery Policy Statement
Virtual Tour
GM Site Sell Sheet